Target intelligence / Profile preview

Blood group B antigen (B antigen)

Target
B antigen
Molecular classification
Carbohydrate antigen, Glycan, Oligosaccharide
01

Overview

The Blood group B antigen is a complex carbohydrate structure expressed on the surface of erythrocytes, endothelial cells, and epithelial cells in individuals with blood type B or AB (StatPearls, NBK554381). It is synthesized by the action of the ABO glycosyltransferase, specifically the B transferase, which attaches an alpha-1,3-linked galactose residue to the H antigen precursor (UniProt, P12432). In clinical medicine, the B antigen is a primary barrier to safe blood transfusion and organ transplantation because individuals with type A or O blood produce pre-existing IgM antibodies against it. These anti-B antibodies can cause rapid, life-threatening intravascular hemolysis if B-positive blood is administered to an incompatible recipient. Research into the B antigen includes the use of specific alpha-galactosidase enzymes to strip the terminal galactose, effectively converting B-type blood into universal O-type blood (Nature Microbiology, s41564-019-0469-7). Additionally, the expression of B antigens on non-erythroid tissues influences susceptibility to various pathogens and the risk of developing certain cardiovascular and oncological conditions (PubMed, 32107131). Management of this target is essential in desensitization protocols for ABO-incompatible organ transplants using therapies like Rituximab and plasmapheresis.

Other names
B substanceABO blood group B antigenGal-alpha-1,3-(Fuc-alpha-1,2)-Gal-beta-1,3/4-GlcNAcType B carbohydrate antigen
02

Mechanism of action

Antibody-mediated agglutination and hemolysis; enzymatic cleavage of the terminal alpha-1,3-galactose residue to convert B antigen to H antigen (Type O).

03

Biological functions

Cell-cell recognitionImmune identityCell adhesionHost-pathogen interaction
04

Disease associations

Hemolytic transfusion reactionHemolytic disease of the newbornOrgan transplant rejectionInfectionCardiovascular diseaseGastric cancer
05

Safety considerations

Acute hemolytic transfusion reactionHyperacute organ rejectionAnaphylaxisCross-reactivity
06

Interacting drugs

Anti-B antibody

3 more in the full profile.

07

Biomarkers

Blood type BAnti-B antibody titerSecretor status

Beyond the preview

Go deeper on Blood group B antigen (B antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blood group B antigen (B antigen).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call